Grace focuses her practice on advising health plans, pharmacy benefit managers (PBMs), rebate aggregators, health care providers, and private equity firms on regulatory, transactional, and compliance matters. She serves as regulatory counsel to health care industry investors in transactions involving a range of health care targets and advises clients on structuring agreements that adapt to evolving regulatory frameworks and advance long-term business goals.
Drawing on her background as a registered nurse, Grace offers industry insight and a practical, commercially informed lens to contract negotiations, regulatory compliance matters, and complex transactions.
During law school, Grace interned with the US Department of Health and Human Services, serving both the Office of Counsel to the Inspector General and the Centers for Medicare & Medicaid Services, Office of the General Counsel. Prior to her legal career, Grace practiced as a registered nurse in a pediatric intensive care unit.
Grace earned her JD from the George Washington University Law School, where she was a member of the Business and Finance Law Review and a Health & FDA Law fellow. She also holds an MS in nursing from Columbia University and a BS in kinesiology and public health from Miami University.
Grace is based in the Washington, DC office.
viewpoints
States Continue to Advance New PBM and Drug Pricing Legislation in 2026
April 9, 2026 | Blog | By Theresa Carnegie, Grace Callander, Sarah Trautz
While federal and state legislators contemplate the next wave of PBM and drug pricing reform, legislatures in Virginia and Ohio have already sent significant legislation addressing prescription drug pricing and pharmacy benefit manager oversight to their respective governors in early 2026.
Federal and State Policymakers Push Forward with PBM and Drug Pricing Reform Even in the Wake of Sweeping Actions Earlier this Year
April 8, 2026 | Blog | By Theresa Carnegie, Grace Callander, Sarah Trautz
Despite the flurry of reform activity throughout the first quarter of 2026, the pace of new PBM regulation and drug pricing reforms shows no sign of tapering off. Instead, both federal and state legislatures continue to target PBMs and drug pricing practices.
